Daewoong Pharmaceutical presents study on Fexuclue at DDW 2024
Daewoong Pharmaceutical presented research on the efficacy of its potassium-competitive acid blocker (P-CAB) class gastroesophageal reflux disease (GERD) treatment, Fexuclue, at the Digestive Disease Week 2024 (DDW 2024) in Washington D.C., held from last …